The U.S. Food and Drug Administration on April 21, 2026, approved Merck’s Idvynso, a once-daily combination pill for HIV treatment that pairs two drug classes in a single tablet. The approval gives ...

Viral reverse transcriptase (RT) plays a critical role in replication (e.g., retroviruses, that reverse transcribe RNA templates into complementary DNA) and genome mutations (e.g., ...

UVA Health researchers say drugs used to treat HIV could help prevent a million new cases of Alzheimer’s each year – and they want clinical trials to find out. UVA’s Dr. Jayakrishna Ambati and his ...

Bacteria defend themselves from viral infection using diverse immune systems, many of which sense and target foreign nucleic acids. Defense-associated reverse transcriptase (DRT) systems provide an ...

Idvynso is a new once-daily, two-drug oral regimen for adults with HIV-1 who are virologically suppressed and have no history of treatment failure.

Newly FDA-approved DOR/ISL offers an INSTI-free, 2-drug HIV treatment option with durable suppression and favorable safety. AJMC: This regimen is the first nonintegrase inhibitor 2-drug combination ...